GlassScriptPhysician profile
Aaron A Weiss
NPI 1700233731
$7,945.58
in general payments reported to CMS, 2019-2025
30 companies · $2,341 in 2025
The $2,341 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $89.94 · 2023: $3,219 · 2024: $2,296 · 2025: $2,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,980 · Travel and Lodging: $706 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,979.61 |
| Travel and Lodging | $705.60 |
| Education | $170.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,569.83 | 2023-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,148.21 | 2023-2025 | Tremfya, Stelara |
| Medtronic, INC. | $1,008.61 | 2023 | Endoflip |
| Lilly USA, LLC | $458.44 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $409.22 | 2023-2025 | Zymfentra, Vegzelma, Yuflyma |
| Takeda Pharmaceuticals U.S.A., INC. | $380.07 | 2023-2025 | Entyvio, Eohilia |
| Pfizer INC. | $330.65 | 2023-2025 | |
| Celgene Corporation | $323.20 | 2023-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.65 | 2023-2025 | Xifaxan |
| Pharmacosmos Therapeutics INC. | $229.82 | 2023 | Monoferric |
| Madrigal Pharmaceuticals | $223.30 | 2024-2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $198.56 | 2023-2024 | Dificid, Zinplava |
| Ardelyx, INC. | $177.75 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $147.99 | 2024 | Voquezna |
| Novo Nordisk INC | $144.80 | 2025 | Wegovy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $142.93 | 2023-2025 | Sucraid |
| E.R. Squibb & Sons, L.L.C. | $139.70 | 2023 | Zeposia |
| Gilead Sciences, INC. | $95.80 | 2023-2024 | |
| Genzyme Corporation | $92.89 | 2025 | |
| Nestle Healthcare Nutrition INC. | $91.11 | 2023 | |
| Braintree Laboratories, INC. | $76.01 | 2023-2025 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $48.36 | 2023-2024 | Ocaliva |
| Fresenius Kabi USA, LLC | $38.86 | 2023 | Idacio |
| Cumberland Pharmaceuticals, INC. | $38.07 | 2023 | Kristalose |
| Ironwood Pharmaceuticals, INC | $22.47 | 2023 | Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.89 | 2023 | |
| Evoke Pharma, INC. | $15.92 | 2023 | Gimoti |
| Axonics, INC. | $15.63 | 2023 | Axonics |
| Lucid Diagnostics INC. | $14.08 | 2023 | |
| Redhill Biopharma INC. | $13.82 | 2024 | Aemcolo, Talicia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.